Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144769 | 0.97 | HPGDS (0.46) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL16438131 | 0.97 | HPGDS (0.46) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL12068463 | 0.95 | CYP3A4 (0.45) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL13171583 | 0.95 | CYP3A4 (0.45) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10144780 | 0.92 | HPGDS (0.41) | CHEK2HPGDSPRCPHCRTR1HCRTR2 | |
| SCHEMBL16405113 | 0.92 | MLLT1 (0.42) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL16438132 | 0.91 | HPGDS (0.39) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10144773 | 0.91 | HPGDS (0.39) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL10144792 | 0.90 | HPGDS (0.53) | HPGDSCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL16441302 | 0.89 | HCRTR1 (0.41) | CHEK2HPGDSCYP3A4CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CHEK2 2799/4885HPGDS 2085/4885CYP3A4 2538/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CHEK2 2799/4885HPGDS 2085/4885CYP3A4 2538/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CHEK2 2799/4885HPGDS 2085/4885CYP3A4 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.